| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14656566.2011.525219 |
| P698 | PubMed publication ID | 21294653 |
| P2093 | author name string | Kalathil K Sureshkumar | |
| Imran Dosani | |||
| Jeannie P Co | |||
| Jessica G Lucas | |||
| Uzoamaka T Nwaogwugwu | |||
| P2860 | cites work | A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection | Q44197767 |
| Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection | Q44469234 | ||
| Rituximab as treatment for refractory kidney transplant rejection | Q44899030 | ||
| Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin | Q44913849 | ||
| Approval summary for bortezomib for injection in the treatment of multiple myeloma | Q44951957 | ||
| Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection | Q45061984 | ||
| Mycophenolate mofetil: how to further improve using an already successful drug? | Q45219583 | ||
| Novel rescue therapy for C4d-positive acute humoral renal allograft rejection | Q45230203 | ||
| Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection | Q45259438 | ||
| Impact of rituximab therapy for treatment of acute humoral rejection | Q45361905 | ||
| Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation | Q46270876 | ||
| Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production | Q46270888 | ||
| Detectable circulating antiendothelial cell antibodies in renal allograft recipients with C4d-positive acute rejection: a report of three cases | Q46562321 | ||
| Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action | Q46681755 | ||
| Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. | Q47726666 | ||
| Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. | Q47862854 | ||
| Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection | Q47869308 | ||
| Predicting kidney graft failure by HLA antibodies: a prospective trial. | Q51038562 | ||
| Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. | Q51736686 | ||
| Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation. | Q53310440 | ||
| The effect of desensitization protocols on human splenic B-cell populations in vivo. | Q53575915 | ||
| "Hyperacute" renal-homograft rejection in man. | Q54626072 | ||
| The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection | Q28299356 | ||
| A phase 2 study of bortezomib in relapsed, refractory myeloma | Q33348702 | ||
| Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection | Q33382552 | ||
| Proteasome inhibition reduces donor-specific antibody levels | Q33383491 | ||
| Abrogation of anti-HLA antibodies via proteasome inhibition | Q33384617 | ||
| Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment | Q34977911 | ||
| Differential outcomes in 3 types of acute antibody-mediated rejection | Q34993432 | ||
| Complement C4d in graft capillaries -- the missing link in the recognition of humoral alloreactivity | Q35142594 | ||
| Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications | Q35142598 | ||
| Antibody to human leukocyte antigen triggers endothelial exocytosis | Q35611613 | ||
| Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols | Q35849009 | ||
| Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients | Q36392146 | ||
| The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection | Q36772871 | ||
| Antibody-mediated rejection following renal transplantation | Q36808030 | ||
| Non-HLA antibodies post-transplantation: clinical relevance and treatment in solid organ transplantation | Q37323165 | ||
| Antibody-mediated rejection: treatment alternatives and outcomes. | Q37332696 | ||
| Deciphering antibody-mediated rejection: new insights into mechanisms and treatment | Q37627522 | ||
| Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. | Q40169580 | ||
| Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection | Q43166691 | ||
| Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies | Q43178469 | ||
| Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation | Q43241188 | ||
| Combined therapy of deoxyspergualin and plasmapheresis: a useful treatment for antibody-mediated acute rejection after kidney transplantation | Q43483642 | ||
| High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis | Q43906723 | ||
| Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure | Q43918875 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| kidney transplantation | Q740909 | ||
| P304 | page(s) | 579-592 | |
| P577 | publication date | 2011-02-05 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Antibody-mediated rejection in kidney transplantation: an update | |
| P478 | volume | 12 |
| Q42280145 | Acute antibody-mediated rejection in pediatric kidney transplants: a single center experience |
| Q51333222 | Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab. |
| Q90730885 | Antibody-Mediated Rejection Treatment With Bortezomib in Renal Transplant Recipients: A Single-Center 24-Month Follow-up Case Report |
| Q38206175 | Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options |
| Q47773036 | Antibody-mediated rejection in young kidney transplant recipients: the dilemma of noncompliance and insufficient immunosuppression |
| Q42553965 | Antibody-mediated rejection: pathogenesis, prevention, treatment, and outcomes |
| Q36365811 | Challenges and considerations in diagnosing the kidney disease in deteriorating graft function |
| Q40967497 | Chronic rejection: Differences and similarities in various solid organ transplants |
| Q93188012 | Comparing Plasmapheresis plus IVIg with Plasmapheresis plus IVIg plus Rituximab on the Management of Suspicious Antibody-Mediated Acute Rejection in Kidney Transplant Recipients |
| Q26829789 | Current state of renal transplant immunosuppression: Present and future |
| Q34841849 | Diagnosis and management of antibody-mediated rejection: current status and novel approaches |
| Q50856320 | Dynamic analysis of B-cell subsets in de novo living related kidney transplantation with induction therapy of basiliximab. |
| Q33404327 | Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports |
| Q27027082 | Effector mechanisms of rejection |
| Q47362322 | Effects of sotrastaurin, mycophenolic acid and everolimus on human B-lymphocyte function and activation |
| Q49644436 | Graft immunologic events in deceased donor kidney transplant recipients with preformed HLA-donor specific antibodies |
| Q33895312 | Host-based Th2 cell therapy for prolongation of cardiac allograft viability |
| Q39968188 | Off-label use of the expensive orphan drug eculizumab in France 2009-2013 and the impact of literature: focus on the transplantation field |
| Q30544649 | Pros and cons for C4d as a biomarker |
| Q44821162 | Successful treatment of severe ABO antibody-mediated rejection using bortezomib: a case report |
| Q36644337 | The Peripheral NK Cell Repertoire after Kidney Transplantation is Modulated by Different Immunosuppressive Drugs |
| Q27021227 | The importance of C4d in biopsies of kidney transplant recipients |
| Q37992871 | The role of therapeutic apheresis in the treatment of acute antibody-mediated kidney rejection |
| Q36054757 | The spleen is the major source of antidonor antibody-secreting cells in murine heart allograft recipients |
| Q36238896 | Treatment of Late Class II Antibody-Mediated Rejection Status Postkidney Transplantation: Two Case Reports |
| Q27021397 | Treatment options and strategies for antibody mediated rejection after renal transplantation |
Search more.